Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tyzivumab in ZIKV Infected Patients
NCT03776695Phase 1Withdrawn
- Sponsor
- Tychan
- Start
- Oct 2018
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of tyzivumab in Zika virus infection (8 arms), sponsored by Tychan. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 84 Days. Planned start Oct 2018; status: withdrawn.
02
Drugs
tyzivumab
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT03776695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776695.